Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial
Plimack E, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross E, Grundy E, Choi W, Dinney C, Lee I, Fong M, Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner S, Flaig T, McConkey D. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. European Urology 2024, 86: 297-300. PMID: 39003201, PMCID: PMC11416320, DOI: 10.1016/j.eururo.2024.06.018.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerCisplatin-based chemotherapyNeoadjuvant chemotherapyBladder cancerTumor samplesNeoadjuvant cisplatin-based chemotherapyResponse to NACClinical assessmentDose-dense methotrexateTiming of cystectomyPathological complete responseClinical trials of chemotherapyTrials of chemotherapyNational clinical trialNeoadjuvant gemcitabineBladder preservationComplete responseTumor specimensSurgical specimensMulticenter trialPatient selectionTreatment armsGene panelChemotherapyGene mutationsPredicting clinical outcomes in the S1314-COXEN trial using a multimodal deep learning model integrating histopathology, cell types, and gene expression.
Faltas B, Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Lucia M, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Wang F. Predicting clinical outcomes in the S1314-COXEN trial using a multimodal deep learning model integrating histopathology, cell types, and gene expression. Journal Of Clinical Oncology 2024, 42: 533-533. DOI: 10.1200/jco.2024.42.4_suppl.533.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerResponse to NACNeoadjuvant chemotherapyPathological response to NACOutcomes of neoadjuvant chemotherapyResponse to neoadjuvant chemotherapyPrediction of response to neoadjuvant chemotherapyCell typesNAC responseDevelopment of precision therapiesOptimize treatment outcomesGene set analysisPredicting cell typesGemcitabine-cisplatinRNA expression dataTumor microenvironmentPathological responseBladder cancerClinical outcomesGene expression vectorPrecision therapyClinical trialsTreatment outcomesStromal cellsBasal differentiation